Therapeutic Pipeline
MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:
- MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
- MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
- MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
- MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.
|
Therapeutic Candidate |
Indication |
Discovery Optimization |
Preclinical Development |
Phase 1 |
Phase 2 |
Phase 3 |
|
MCT-125 |
PMSF |
|
|
|
|
|
|
MCT-465 |
Cancer |
|
|
|
|
|
|
MCT-475 |
Cancer |
|
|
|
|
|
|
MCT-485 |
Cancer |
|
|
|
|
|